Prof. Cummings (Portsmouth, UK)

The simplicity of Trajenta® is exactly that –Firstly, that we see an established efficacy in terms of HbA_1c reduction. Secondly, an established safety profile with its use. And thirdly, the simple convenience of a once-daily preparation. The simplicity of Trajenta® means that we can use it in a wide range of patients. So diabetes is a very heterogeneous condition –we see patients with varying age, varying BMI, renal function, hepatic function, risk of hyperglycaemia, on a wide variety of glucose-lowering therapies. So this is an agent that we can use in all these situations. In addition, it’s once-daily dosing without having to adjust the dose of the therapy so it is a very simple approach with the use of Trajenta®.